Sharma S - Search Results

1

Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells.

Gupta S, Doyle K, Mosbruger TL, Butterfield A, Weston A, Ast A, Kaadige M, Verma A, Sharma S. Gupta S, et al. Among authors: sharma s. Oncotarget. 2018 Jan 6;9(11):9907-9924. doi: 10.18632/oncotarget.24035. eCollection 2018 Feb 9. Oncotarget. 2018. PMID: 29515779 Free PMC article.

2

Targeting Axl and Mer kinases in cancer.

Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S. Verma A, et al. Among authors: sharma s. Mol Cancer Ther. 2011 Oct;10(10):1763-73. doi: 10.1158/1535-7163.MCT-11-0116. Epub 2011 Sep 20. Mol Cancer Ther. 2011. PMID: 21933973 Review.

3

Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.

Mollard A, Warner SL, Call LT, Wade ML, Bearss JJ, Verma A, Sharma S, Vankayalapati H, Bearss DJ. Mollard A, et al. Among authors: sharma s. ACS Med Chem Lett. 2011 Dec 8;2(12):907-912. doi: 10.1021/ml200198x. ACS Med Chem Lett. 2011. PMID: 22247788 Free PMC article.

4

Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.

Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN. Ha K, et al. Among authors: sharma s. Oncotarget. 2014 Jul 30;5(14):5637-50. doi: 10.18632/oncotarget.2154. Oncotarget. 2014. PMID: 25026298 Free PMC article.

5

Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-Catenin Pathway Inhibitors.

Soldi R, Horrigan SK, Cholody MW, Padia J, Sorna V, Bearss J, Gilcrease G, Bhalla K, Verma A, Vankayalapati H, Sharma S. Soldi R, et al. Among authors: sharma s. J Med Chem. 2015 Aug 13;58(15):5854-62. doi: 10.1021/acs.jmedchem.5b00460. Epub 2015 Jul 31. J Med Chem. 2015. PMID: 26182238

6

A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin.

Agarwal N, McPherson JP, Bailey H, Gupta S, Werner TL, Reddy G, Bhat G, Bailey EB, Sharma S. Agarwal N, et al. Among authors: sharma s. Cancer Chemother Pharmacol. 2016 Feb;77(2):299-308. doi: 10.1007/s00280-015-2934-1. Epub 2015 Dec 30. Cancer Chemother Pharmacol. 2016. PMID: 26719074 Clinical Trial.

7

Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation.

Gupta S, Gouw L, Wright J, Chawla S, Pitt D, Wade M, Boucher K, Sharma S. Gupta S, et al. Among authors: sharma s. Invest New Drugs. 2016 Apr;34(2):243-52. doi: 10.1007/s10637-016-0333-z. Epub 2016 Feb 20. Invest New Drugs. 2016. PMID: 26897615 Clinical Trial.

8

Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.

Gupta S, Weston A, Bearrs J, Thode T, Neiss A, Soldi R, Sharma S. Gupta S, et al. Among authors: sharma s. Prostate Cancer Prostatic Dis. 2016 Dec;19(4):349-357. doi: 10.1038/pcan.2016.21. Epub 2016 Jun 28. Prostate Cancer Prostatic Dis. 2016. PMID: 27349498 Free PMC article.

9

A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors.

Bailey H, McPherson JP, Bailey EB, Werner TL, Gupta S, Batten J, Reddy G, Bhat G, Sharma S, Agarwal N. Bailey H, et al. Among authors: sharma s. Cancer Chemother Pharmacol. 2016 Nov;78(5):1059-1071. doi: 10.1007/s00280-016-3167-7. Epub 2016 Oct 15. Cancer Chemother Pharmacol. 2016. PMID: 27744565 Clinical Trial.

10

Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma.

Gupta S, Albertson DJ, Parnell TJ, Butterfield A, Weston A, Pappas LM, Dalley B, O'Shea JM, Lowrance WT, Cairns BR, Schiffman JD, Sharma S. Gupta S, et al. Among authors: sharma s. Mol Cancer Ther. 2019 Jan;18(1):185-195. doi: 10.1158/1535-7163.MCT-17-0957. Epub 2018 Oct 9. Mol Cancer Ther. 2019. PMID: 30301863 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23,906 results

Search Page